SCHEMBL8936767

SCHEMBL8936767

COCOc1ccc(C(F)(F)F)cc1C=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.44
HTT P42858 2/20 0.44
KMT2A Q03164 2/20 0.44
ALDH1A1 P00352 6/20 0.41
HPGD P15428 2/20 0.41
HSD17B10 Q99714 1/20 0.41
L3MBTL1 Q9Y468 3/20 0.40
POLB P06746 2/20 0.40
MAPT P10636 4/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
PTGDR2 Q9Y5Y4 3/20 0.38
MEN1 O00255 1/20 0.37
BACE1 P56817 1/20 0.37
LMNA P02545 1/20 0.37
ATM Q13315 1/20 0.37
FDPS P14324 1/20 0.36
PPARG P37231 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22090747 0.88 POLB (0.41) KDM4EHTTKMT2AALDH1A1HPGD
SCHEMBL27340001 0.84 CYP1A2 (0.54) KDM4EHTTKMT2AALDH1A1HPGD
SCHEMBL23393432 0.83 PTGDR2 (0.47) KDM4EHTTKMT2AALDH1A1HPGD
SCHEMBL1186123 0.82 ALDH1A1 (0.50) KDM4EKMT2AALDH1A1HPGDL3MBTL1
SCHEMBL19524145 0.81 SCN8A (0.46) KDM4EHTTKMT2AALDH1A1HPGD
SCHEMBL19524202 0.80 SCN8A (0.46) KDM4EHTTKMT2AALDH1A1HPGD
SCHEMBL8686048 0.80 ALDH1A1 (0.55) KDM4EKMT2AALDH1A1HPGDPOLB
SCHEMBL31254214 0.80 ALDH1A1 (0.55) KDM4EKMT2AALDH1A1HPGDPOLB
SCHEMBL8710140 0.79 BACE1 (0.43) KDM4EKMT2AALDH1A1MAPTPTGDR2
SCHEMBL6823190 0.79 CYP1A2 (0.40) KDM4EHTTKMT2AALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240083861-A1 HSD17B13 INHIBITORS AND USES THEREOF FL2022-001, INC. 2024-03-14 US disclosed
US-5587392-A THERAPY FOR ESTROGEN DEPENDENT DISEASES MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 1996-12-24 US disclosed
EP-0684235-A1 Novel azolyl methyl phenyl derivatives having aromatase inhibitory activity MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 1995-11-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240083861-A1 HSD17B13 INHIBITORS AND USES THEREOF HSD17B3, HSD17B11, HSD17B1 KDM4E 3909/4885HTT 1888/4885KMT2A 3736/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.